QR-Code

Structural insight into the macrocyclic inhibitor TPX-0022 of c-Met and c-Src

c-Met has been an attractive target of prognostic and therapeutic studies in various cancers. TPX-0022 is a macrocyclic inhibitor of c-Met, c-Src and CSF1R kinases and is currently in phase I/II clinical trials in patients with advanced solid tumors harboring MET gene alterations. In this study, we...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Lingzhi Qu, Hang Lin, Shuyan Dai, Ming Guo, Xiaojuan Chen, Longying Jiang, Huajun Zhang, Maoyu Li, Xunjun Liang, Zhuchu Chen, Hudie Wei, Yongheng Chen
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Association for the Advancement of Science (AAAS) 2023-01-01
Schriftenreihe:Computational and Structural Biotechnology Journal
Schlagworte:
C-Met
TPX-0022
Crystal structure
Resistance-relevant mutations
C-Src
Online-Zugang:http://www.sciencedirect.com/science/article/pii/S2001037023004439
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge